Oregon Public Employees Retirement Fund Increases Stake in Johnson & Johnson $JNJ

Oregon Public Employees Retirement Fund increased its holdings in Johnson & Johnson (NYSE:JNJ) by 32.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 275,313 shares of the company’s stock after acquiring an additional 67,384 shares during the quarter. Johnson & Johnson makes up about 0.7% of Oregon Public Employees Retirement Fund’s investment portfolio, making the stock its 20th largest position. Oregon Public Employees Retirement Fund’s holdings in Johnson & Johnson were worth $51,049,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in JNJ. SOA Wealth Advisors LLC. boosted its stake in shares of Johnson & Johnson by 0.7% during the third quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock valued at $1,371,000 after purchasing an additional 53 shares in the last quarter. Ethos Financial Group LLC lifted its holdings in Johnson & Johnson by 0.6% during the third quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock worth $1,689,000 after buying an additional 53 shares during the period. Heritage Oak Wealth Advisors LLC boosted its position in Johnson & Johnson by 3.5% during the 3rd quarter. Heritage Oak Wealth Advisors LLC now owns 1,639 shares of the company’s stock valued at $304,000 after acquiring an additional 55 shares in the last quarter. Lifestyle Asset Management Inc. increased its holdings in shares of Johnson & Johnson by 3.4% in the 3rd quarter. Lifestyle Asset Management Inc. now owns 1,683 shares of the company’s stock valued at $312,000 after acquiring an additional 56 shares during the period. Finally, Wynn Capital LLC raised its position in shares of Johnson & Johnson by 0.4% in the 3rd quarter. Wynn Capital LLC now owns 15,930 shares of the company’s stock worth $2,954,000 after acquiring an additional 57 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the topic of several analyst reports. Citigroup lifted their target price on Johnson & Johnson from $215.00 to $232.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Johnson Rice set a $190.00 price objective on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. Barclays increased their target price on shares of Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 30th. JPMorgan Chase & Co. lifted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, December 11th. Four equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $213.33.

Johnson & Johnson Stock Up 2.6%

NYSE:JNJ opened at $209.79 on Tuesday. The company’s 50 day moving average is $203.34 and its two-hundred day moving average is $185.38. The company has a market cap of $505.45 billion, a PE ratio of 20.25, a P/E/G ratio of 2.10 and a beta of 0.34. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $215.18. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion during the quarter. Analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. Johnson & Johnson’s payout ratio is currently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.